Our Pricing

Understanding Wegovy Pen Doses: Complete UK Dosing Guide

Understanding wegovy pen doses uk is essential before starting treatment. Each Wegovy pen contains four single-dose injections designed for once-weekly administration, with a carefully structured dose escalation schedule over five months. At Cured Pharmacy, UK patients access genuine MHRA-licensed Wegovy pens with transparent pricing and expert clinical support throughout their weight management journey.

How Many Doses Are in Each Wegovy Pen?

Every Wegovy pen is a pre-filled, single-use device containing exactly one weekly dose. Unlike multi-dose pens used for some medications, Wegovy pens are designed for single administration only, ensuring precise dosing and reducing contamination risk [1]. Each monthly supply box contains four individual pens—one for each week of the month.

The dose strength varies depending on where you are in the titration schedule. Your first month's box contains four 0.25mg pens, your second month contains four 0.5mg pens, and so forth until you reach the maintenance dose of 2.4mg weekly [1]. This gradual escalation approach, validated in the STEP clinical trial programme, helps minimise gastrointestinal side effects whilst optimising weight loss outcomes [2].

Patients often confuse Wegovy with insulin pens that contain multiple doses. It's crucial to understand that each Wegovy pen is used once and then safely disposed of in a sharps container, which your pharmacy can provide or advise on obtaining through your local council.

Wegovy Dosing Schedule Explained

The complete Wegovy dose escalation follows a structured 20-week titration protocol approved by the MHRA. You begin with 0.25mg weekly for four weeks (month one), then increase to 0.5mg weekly for four weeks (month two), followed by 1mg weekly (month three), 1.7mg weekly (month four), and finally reach the maintenance dose of 2.4mg weekly from month five onwards [1].

This graduated approach isn't arbitrary—clinical data from the STEP-1 trial demonstrated that patients following this specific titration schedule experienced significantly fewer treatment discontinuations due to gastrointestinal adverse events compared to more rapid dose escalation [2]. The average weight reduction at 68 weeks was 14.9% of initial body weight in participants receiving semaglutide 2.4mg, compared to 2.4% with placebo [2].

Your UK prescriber may adjust this schedule based on your individual tolerance and response. Some patients remain on lower maintenance doses if they achieve their weight management goals or experience persistent side effects, whilst others progress through the full titration as planned.

What Happens If You Miss a Dose?

If you miss a Wegovy injection and it's been fewer than five days since your scheduled dose, administer it as soon as you remember, then resume your regular weekly schedule [1]. If more than five days have passed, skip the missed dose entirely and take your next injection on the regularly scheduled day—never double up to compensate for a missed dose.

Missing multiple consecutive doses may require restarting the titration schedule from a lower dose to avoid increased side effects. Your prescriber at Cured Pharmacy can provide personalised guidance if you've experienced dosing interruptions, ensuring safe continuation of treatment.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone in your body [1]. When administered weekly, semaglutide acts on areas of the brain that regulate appetite and food intake, leading to reduced hunger, increased feelings of fullness, and consequently lower caloric intake [3].

The medication also slows gastric emptying—the rate at which food leaves your stomach—which contributes to prolonged satiety after meals [3]. Additionally, semaglutide improves glycaemic control and may reduce cardiovascular risk factors, benefits observed across the STEP trial programme involving over 4,500 participants [2][4].

It's important to understand that Wegovy is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone solution. The most successful outcomes in clinical trials occurred when patients combined medication with comprehensive lifestyle modifications including dietary counselling and exercise programmes [2].

Expected Weight Loss Timeline

Most patients begin noticing appetite reduction within the first few weeks of treatment, though significant weight changes typically emerge after reaching higher doses around months three to four. In the STEP-1 trial, participants achieved an average 14.9% body weight reduction by week 68, with most weight loss occurring between weeks 20 and 60 [2].

Individual results vary considerably based on adherence to lifestyle modifications, baseline metabolic health, and genetic factors. Your UK prescriber will monitor your progress through regular check-ins, typically expecting at least 5% weight loss within the first 12 weeks at maintenance dose to consider treatment effective [1].

Wegovy Pen Doses UK: Administration Technique

Wegovy is administered subcutaneously—injected into the fatty tissue just beneath the skin—in your abdomen, thigh, or upper arm. The abdomen (excluding a 5cm radius around your navel) is often preferred for consistent absorption, though rotating injection sites helps prevent lipodystrophy—changes in fat tissue at injection sites [1].

Each pen comes ready to use with a hidden needle that automatically inserts when pressed firmly against your skin. After checking the medication is clear and colourless (any discolouration means the pen shouldn't be used), remove the pen cap, place the pen perpendicular to your injection site, press the button, and hold for approximately six seconds until you hear a second click indicating the full dose has been delivered [1].

Common administration errors include not holding the pen long enough (resulting in incomplete dosing), injecting through clothing, or failing to rotate sites adequately. Your Cured Pharmacy clinical team provides detailed visual guides and can answer specific technique questions during your consultation to ensure proper administration from your first injection.

Side Effects and Safety Considerations

The most frequently reported side effects with Wegovy are gastrointestinal: nausea (44% of participants in STEP-1), diarrhoea (30%), vomiting (24%), and constipation (24%) [2]. These effects are typically mild to moderate, most common during dose escalation phases, and generally diminish over time as your body adjusts to the medication.

More serious but rare adverse events include pancreatitis, gallbladder problems, and potential thyroid C-cell tumours (observed in rodent studies but not conclusively demonstrated in humans) [1][3]. Wegovy is contraindicated if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Hypoglycaemia risk increases if you're taking Wegovy alongside other glucose-lowering medications like insulin or sulfonylureas—your prescriber will review all current medications during assessment. Pregnant or breastfeeding women should not use Wegovy, and the MHRA recommends discontinuing treatment at least two months before planned conception due to the medication's long half-life [1].

Managing Common Side Effects

To minimise nausea, eat smaller, more frequent meals rather than large portions, avoid high-fat and spicy foods, and stay well-hydrated throughout the day. Many patients find that side effects are most pronounced in the 24-48 hours following injection, so timing your weekly dose before a lighter schedule day may help.

If side effects become intolerable, contact your prescriber before your next dose—remaining at your current dose level for an additional month rather than escalating may allow better tolerance. Never adjust your dosing schedule without clinical guidance from your UK prescriber.

Buying Wegovy Pen Doses UK: What to Expect

At Cured Pharmacy, Wegovy is available with transparent upfront pricing and requires completion of a clinical assessment by a UK-registered prescriber before dispensing. The online consultation takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications to ensure Wegovy is clinically appropriate for you.

Once approved, your prescription is fulfilled using genuine UK-licensed Wegovy manufactured by Novo Nordisk and supplied in temperature-controlled packaging to maintain medication integrity. Delivery is 100% discreet with no external branding, typically arriving within 2-3 working days to any UK address.

Each monthly supply includes four single-dose pens at the appropriate strength for your current titration phase, along with comprehensive patient information leaflets. Ongoing prescriptions require periodic clinical reviews to monitor progress, assess tolerability, and determine continued appropriateness of treatment—this ensures you receive safe, effective care throughout your weight management journey.

Storage and Handling Requirements

Unopened Wegovy pens must be stored in a refrigerator between 2°C and 8°C until first use, and should never be frozen [1]. Once you've started using a pen (after removing the cap), it can be stored at room temperature below 30°C or continued in the refrigerator for up to 28 days.

Always transport pens in their original carton to protect from light, and if travelling, use a cool bag with ice packs (ensuring pens don't directly contact ice). Never store Wegovy in car glove compartments or areas exposed to direct sunlight, as temperature extremes degrade semaglutide and render the medication ineffective.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Nauck, M. A., et al. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary individually and depend on adherence to lifestyle modifications alongside medication use.